Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Completed · Phase 3

Conditions studied: Iron Deficiency Anaemia, Iron Deficiency Anemia

In brief

The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).

Key facts

Study ID

NCT03237065

Run by

Pharmacosmos A/S

People needed

122

Starts

2017-10-30

Expected to finish

2018-05-29

Last updated by the study team

2020-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Pharmacosmos Investigational Site — Muscle Shoals, Alabama, United States
• Pharmacosmos Investigational Site — Doral, Florida, United States
• Pharmacosmos Investigational Site — Miami, Florida, United States
• Pharmacosmos Investigational Site — Miami, Florida, United States
• Pharmacosmos Investigational Site — Miami Lakes, Florida, United States
• Pharmacosmos Investigational Site — Orlando, Florida, United States
• Pharmacosmos Investigational Site — Idaho Falls, Idaho, United States
• Pharmacosmos Investigational Site — Oak Brook, Illinois, United States
• Pharmacosmos investigational Site — Flint, Michigan, United States
• Pharmacosmos Investigational Site — St Louis, Missouri, United States
• Pharmacosmos Investigational Site — Las Vegas, Nevada, United States
• Pharmacosmos Investigational Site — Albuquerque, New Mexico, United States
• Pharmacosmos Investigational Site — Morehead City, North Carolina, United States
• Pharmacosmos Investigational Site — Raleigh, North Carolina, United States
• Pharmacosmos Investigational Site — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.